Sulfaphenazole, CYP2C9 inhibitor (ab145038)

Overview

  • Product name

    Sulfaphenazole, CYP2C9 inhibitor
  • Description

    Selective CYP2C9 inhibitor.
  • Alternative names

    • 2-Phenyl-3-sulfanilamidopyrazole
    • 3-(p-Aminobenzenesulfonamido)-2-phenylpyrazole
    • 4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide
    • 5-Sulfanilamido-1-phenylpyrazole
    • Depocid
    • Depotsulfonamide
    • Eftolon
    • Firmazolo
    • Inamil
    • N1-(1-Phenylpyrazol-5-yl)sulfanilamidopyrazole
    • Plisulfan
    • Raziosulfa
    • SPA
    see all
  • Biological description

    Selective, competitive CYP2C9 inhibitor (Ki = 0.3 µM). Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Inhibits bradykinin-induced tPA release. Sulfonamide antibacterial.

  • CAS Number

    526-08-9
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide
  • Molecular weight

    314.36
  • Molecular formula

    C15H14N4O2S
  • Storage instructions

    Store at Room Temperature. The product can be stored for up to 12 months.
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • Source

    Synthetic

References

This product has been referenced in:

  • Giannarelli C  et al. Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients. Circulation 119:1625-33 (2009). Read more (PubMed: 19289643) »
  • Viswanathan S  et al. Involvement of CYP 2C9 in mediating the proinflammatory effects of linoleic acid in vascular endothelial cells. J Am Coll Nutr 22:502-10 (2003). Read more (PubMed: 14684755) »
  • Melet A  et al. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys 409:80-91 (2003). Read more (PubMed: 12464247) »
  • Giancarlo GM  et al. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol 57:31-6 (2001). Read more (PubMed: 11372587) »
  • Jung F  et al. Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin metabolism to P450 2C19. Biochemistry 37:16270-9 (1998). Read more (PubMed: 9819219) »
  • Mancy A  et al. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry 35:16205-12 (1996). Read more (PubMed: 8973193) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab145038.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up